EUVIMEDEUVIMED entdecken
Metaanalyse

Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials

Bingzi Dong, Yue Zhou, Jun Wang, Chengqian Li, Zhengju Fu, Yajing Huang, Yangang Wang, Lili Xu

Hormone and Metabolic Research · 2023-04 · 55 (04) · 236-244

DOI: 10.1055/a-2015-1747 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Hormone and Metabolic Research, online erschienen am 23.02.2023. Verfasst von Bingzi Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Fractures, Bone. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Shandong Provincial Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis (OP) is characterized as decreased bone mineral density (BMD) and increased risk of bone fracture. Secondary OP resulting from excess endogenous or exogenous glucocorticoid is defined as glucocorticoid-induced osteoporosis (GIOP). Current therapeutic strategies for GIOP are similar to menopausal osteoporosis, including calcium and vitamin D supplementation, bisphosphonates, and parathyroid hormone (PTH) analogues (teriparatide). Previously, several published meta-analyses compared anti-osteoporotic agents for the menopausal or aging-dependent OP. However, the physiopathologic bone metabolism of GIOP is different. In this study, we investigated the efficacy of BMD enhancement, bone fracture rate and safety of bisphosphonates versus teriparatide in the therapy of GIOP. We searched databases including PubMed, Embase, and the Cochrane Library until Jan 2023, and selected ten random clinical trials (RCT)s that compared the efficacy and/or safety of bisphosphonate versus teriparatide for GIOP patients. Teriparatide therapy increased lumber spinal BMD by 3.96% (95% CI 3.01–4.9%, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosisFractures, BoneFemaleHumansTeriparatideDiphosphonatesGlucocorticoidsBone DensityRandomized Controlled Trials as Topic

Substanzen

TeriparatideDiphosphonatesGlucocorticoidsBone Density Conservation Agents

Autor:innen und Institutionen

  • Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Endocrinology, Fudan University, Shanghai, China.

Förderung

  • Shandong Provincial Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Dong, B., Zhou, Y., Wang, J., Li, C., Fu, Z., Huang, Y., Wang, Y., & Xu, L. (2023). Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials. Hormone and Metabolic Research, 55(04), 236-244. https://doi.org/10.1055/a-2015-1747

Vancouver

Dong B, Zhou Y, Wang J, Li C, Fu Z, Huang Y, et al. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials. Hormone and Metabolic Research. 2023;55(04):236-244. doi:10.1055/a-2015-1747

BibTeX
@article{Dong2023,
  author = {Dong, Bingzi and Zhou, Yue and Wang, Jun and Li, Chengqian and Fu, Zhengju and Huang, Yajing and Wang, Yangang and Xu, Lili},
  title = {Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials},
  journal = {Hormone and Metabolic Research},
  year = {2023},
  volume = {55},
  number = {04},
  pages = {236--244},
  doi = {10.1055/a-2015-1747}
}
Kostenlos starten →